Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate

Dimethyl fumarate (DMF) is the most recent oral disease-modifying therapy approved by the US Food and Drug Administration and is indicated for the treatment of relapsing forms of multiple sclerosis (MS). Prior to approval for use in MS, DMF and its active metabolite, monomethyl fumarate, had been us...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicholas, Jacqueline Ann, Boster, Aaron Lee, Imitola, Jaime, O’Connell, Colleen, Racke, Michael Karl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094574/
https://www.ncbi.nlm.nih.gov/pubmed/25045248
http://dx.doi.org/10.2147/DDDT.S50962

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094574/
https://www.ncbi.nlm.nih.gov/pubmed/25045248
http://dx.doi.org/10.2147/DDDT.S50962

Ejemplares similares